PMID- 21601111
OWN - NLM
STAT- MEDLINE
DCOM- 20110929
LR  - 20141120
IS  - 0242-6498 (Print)
IS  - 0242-6498 (Linking)
VI  - 31
IP  - 2
DP  - 2011 Apr
TI  - [HER2 and gastric cancer. Recommendations for clinical practice in 2011].
PG  - 78-87
LID - 10.1016/j.annpat.2011.03.001 [doi]
AB  - Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin has 
      been approved by the European Medicines Agency (EMEA) for the treatment of 
      patients with human epidermal growth factor receptor 2 (HER2)-positive 
      (immunohistochemistry [IHC] 3+ or IHC 2+/ fluorescence in situ hybridization 
      [FISH]-positive or IHC 2+/ silver in situ hybridization [SISH]-positive) 
      metastatic adenocarcinoma of the stomach or gastro-esophageal (GE) junction. HER2 
      testing in gastric cancer (GC) differs from testing in breast cancer (BC) due to 
      major differences in the tumor biology; as the disease is progressing rapidely, 
      we recommend to test every GC at diagnosis and to offer a rapid testing (less 
      than five days) in the metastatic setting. IHC should be the initial testing 
      methodology and FISH or SISH should be used to retest IHC 2+ samples. As GC more 
      frequently shows incomplete membrane staining and focal staining for HER2, HER2 
      testing guidelines have been adapted from BC protocols. The scoring system is 
      slightly different in respect to the characteristics of GC. For in situ 
      hybridization, SISH should be used in order to identify heterogeneous staining 
      with a higher accuracy than FISH. Enrollment in training and quality assurance 
      programs is highly recommended. In case of negativity on biopsy, it is 
      recommended to retest for HER2, when possible, on surgical specimens and/or 
      metastasis. This will ensure accurate and consistent HER2 testing results, which 
      will allow the appropriate selection of patients eligible for treatment with 
      trastuzumab.
CI  - Copyright (c) 2011. Published by Elsevier Masson SAS.
FAU - Penault-Llorca, Frederique
AU  - Penault-Llorca F
AD  - Departement de pathologie, centre Jean-Perrin, BP 392, 58, rue Montalembert, 
      63011 Clermont-Ferrand cedex, France; EA 4233, universite d'Auvergne, 63000 
      Clermont-Ferrand cedex, France. fpenault@cjp.fr
FAU - Chenard, Marie-Pierre
AU  - Chenard MP
FAU - Bouche, Olivier
AU  - Bouche O
FAU - Emile, Jean-Francois
AU  - Emile JF
FAU - Bibeau, Frederic
AU  - Bibeau F
FAU - Metges, Jean-Philippe
AU  - Metges JP
FAU - Andre, Thierry
AU  - Andre T
FAU - Monges, Genevieve
AU  - Monges G
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Practice Guideline
TT  - HER2 et cancer gastrique. Recommandations pour la pratique clinique en 2011.
DEP - 20110507
PL  - France
TA  - Ann Pathol
JT  - Annales de pathologie
JID - 8106337
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/chemistry/*pathology
MH  - Humans
MH  - *Receptor, ErbB-2/analysis
MH  - Stomach Neoplasms/chemistry/*pathology
EDAT- 2011/05/24 06:00
MHDA- 2011/10/01 06:00
CRDT- 2011/05/24 06:00
PHST- 2010/12/30 00:00 [received]
PHST- 2011/03/09 00:00 [revised]
PHST- 2011/03/12 00:00 [accepted]
PHST- 2011/05/24 06:00 [entrez]
PHST- 2011/05/24 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
AID - S0242-6498(11)00048-4 [pii]
AID - 10.1016/j.annpat.2011.03.001 [doi]
PST - ppublish
SO  - Ann Pathol. 2011 Apr;31(2):78-87. doi: 10.1016/j.annpat.2011.03.001. Epub 2011 
      May 7.